Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate cancer, they knew they needed to understand how this genetic alteration was driving cancer and how to target it with treatment.